IL6 and COVID-19: Although in vitro treatment of COVID-19 plasma with low molecular weight heparin (LMWH) and heparan sulfate mimetic minimised glycocalyx perturbation, and LMWH was shown to reduce IL-6 levels in COVID-19 patients16,28.